Press Releases

Date	Title	PDF Version
Sep 04, 2015	Alexion Receives Notification of PDUFA Date Extension for Kanuma™ (sebelipase alfa)
Sep 03, 2015	Alexion to Present at the 2015 Morgan Stanley Global Healthcare Conference
Sep 01, 2015	European Commission Grants Marketing Authorization for Strensiq™ (asfotase alfa) for the Treatment of Patients with Pediatric-Onset Hypophosphatasia (HPP)
Sep 01, 2015	European Commission Grants Marketing Authorization for Kanuma™ (sebelipase alfa) for the Treatment of Patients of All Ages with Lysosomal Acid Lipase Deficiency (LAL-D)
Jul 30, 2015	Alexion Reports Second Quarter 2015 Results
Jul 13, 2015	Alexion Pharmaceuticals to Report Second Quarter 2015 Results on Thursday, July 30, 2015
Jul 06, 2015	Strensiq® (asfotase alfa) Receives Marketing Approval in Japan for Treatment of Patients with Hypophosphatasia (HPP)
Jun 26, 2015	Alexion Receives CHMP Positive Opinions for Strensiq™ (asfotase alfa) and Kanuma™ (sebelipase alfa) in the European Union
Jun 23, 2015	Alexion Completes Acquisition of Synageva
Jun 22, 2015	Alexion Accepts Shares of Synageva BioPharma Corp. Tendered Into Exchange Offer

Search